Dr. Aladjem received her Ph.D. from Tel Aviv University. She was a research associate at the Weizmann Institute of Science and then a postdoctoral fellow and a Leukemia Society Special Fellow at the Salk Institute in La Jolla, California. Dr. Aladjem joined the Laboratory of Molecular Pharmacology/Developmental Therapeutics Branch in October 1999 and was appointed a Senior Investigator in 2007. Dr. Aladjem's studies focus on cellular signaling pathways that modulate chromatin to regulate chromosome duplication and cell cycle progression.